{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:18:14Z","timestamp":1782346694909,"version":"3.54.5"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T00:00:00Z","timestamp":1493683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T00:00:00Z","timestamp":1493683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"German Federal Ministry of Education and Research","award":["01KG1305"],"award-info":[{"award-number":["01KG1305"]}]},{"name":"European Academy for Dermatology and Venereology","award":["2016-012"],"award-info":[{"award-number":["2016-012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s40265-017-0746-9","type":"journal-article","created":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T08:34:34Z","timestamp":1493714074000},"page":"999-1007","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Chronic Pruritus: Current and Emerging Treatment Options"],"prefix":"10.1007","volume":"77","author":[{"given":"Manuel P.","family":"Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"St\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,2]]},"reference":[{"issue":"1","key":"746_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2340\/00015555-2166","volume":"96","author":"ME Kopyciok","year":"2016","unstructured":"Kopyciok ME, Stander HF, Osada N, et al. Prevalence and characteristics of pruritus: a one-week cross-sectional study in a German dermatology practice. Acta Derm Venereol. 2016;96(1):50\u20135.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"746_CR2","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/jid.2013.446","volume":"134","author":"RJ Hay","year":"2014","unstructured":"Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(6):1527\u201334.","journal-title":"J Invest Dermatol."},{"issue":"3","key":"746_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000319862","volume":"221","author":"S Stander","year":"2010","unstructured":"Stander S, Schafer I, Phan NQ, et al. Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730. Dermatology. 2010;221(3):229\u201335.","journal-title":"Dermatology"},{"key":"746_CR4","doi-asserted-by":"crossref","unstructured":"Stander S, Zeidler C, Magnolo N, et al. Clinical management of pruritus. J Dtsch Dermatol Ges. 2015;13(2):101\u201315 (quiz 116).","DOI":"10.1111\/ddg.12522_suppl"},{"issue":"3","key":"746_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1600-0625.2007.00664.x","volume":"17","author":"S Stander","year":"2008","unstructured":"Stander S, Weisshaar E, Luger TA. Neurophysiological and neurochemical basis of modern pruritus treatment. Exp Dermatol. 2008;17(3):161\u20139.","journal-title":"Exp Dermatol"},{"issue":"4","key":"746_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2340\/00015555-0305","volume":"87","author":"S Stander","year":"2007","unstructured":"Stander S, Weisshaar E, Mettang T, et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol. 2007;87(4):291\u20134.","journal-title":"Acta Derm Venereol"},{"key":"746_CR7","unstructured":"St\u00e4nder S, Zeidler C, Augustin M, et al. S2k-Guideline - Chronic Pruritus. J Dtsch Dermatol Ges. 2017 (in press)."},{"issue":"5","key":"746_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2340\/00015555-1400","volume":"92","author":"E Weisshaar","year":"2012","unstructured":"Weisshaar E, Szepietowski JC, Darsow U, et al. European guideline on chronic pruritus. Acta Derm Venereol. 2012;92(5):563\u201381.","journal-title":"Acta Derm Venereol"},{"key":"746_CR9","doi-asserted-by":"crossref","unstructured":"Yamaura K, Doi R, Suwa E, Ueno K. Repeated application of glucocorticoids exacerbate pruritus via inhibition of prostaglandin D2 production of mast cells in a murine model of allergic contact dermatitis. J Toxicol Sci. 2012;37(6):1127\u201334.","DOI":"10.2131\/jts.37.1127"},{"issue":"4","key":"746_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1159\/000355671","volume":"227","author":"D Siepmann","year":"2013","unstructured":"Siepmann D, Lotts T, Blome C, et al. Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial. Dermatology. 2013;227(4):353\u201360.","journal-title":"Dermatology"},{"issue":"24","key":"746_CR11","first-page":"3927","volume":"18","author":"A Osmola-Mankowska","year":"2014","unstructured":"Osmola-Mankowska A, Polanska A, Silny W, et al. Topical tacrolimus vs medium-dose ultraviolet al phototherapy in the treatment of atopic dermatitis: a preliminary study in relation to parameters of the epidermal barrier function and high-frequency ultrasonography. Eur Rev Med Pharmacol Sci. 2014;18(24):3927\u201334.","journal-title":"Eur Rev Med Pharmacol Sci."},{"issue":"3","key":"746_CR12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1159\/000354911","volume":"227","author":"A Stumpf","year":"2013","unstructured":"Stumpf A, Stander S, Phan NQ, et al. Body concept of patients with chronic pruritus in relation to scratch lesions and psychic symptoms. Dermatology. 2013;227(3):263\u20139.","journal-title":"Dermatology"},{"issue":"4","key":"746_CR13","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/pai.12331","volume":"26","author":"T Luger","year":"2015","unstructured":"Luger T, Boguniewicz M, Carr W, et al. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol. 2015;26(4):306\u201315.","journal-title":"Pediatr Allergy Immunol"},{"issue":"1","key":"746_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000381948","volume":"231","author":"X Huang","year":"2015","unstructured":"Huang X, Xu B. Efficacy and safety of tacrolimus versus pimecrolimus for the treatment of atopic dermatitis in children: a network meta-analysis. Dermatology. 2015;231(1):41\u20139.","journal-title":"Dermatology"},{"key":"746_CR15","first-page":"293","volume":"68","author":"K Boyd","year":"2014","unstructured":"Boyd K, Shea SM, Patterson JW. The role of capsaicin in dermatology. Prog Drug Res. 2014;68:293\u2013306.","journal-title":"Prog Drug Res"},{"issue":"2","key":"746_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/jcp.20061","volume":"201","author":"TM O\u2019Connor","year":"2004","unstructured":"O\u2019Connor TM, O\u2019Connell J, O\u2019Brien DI, et al. The role of substance P in inflammatory disease. J Cell Physiol. 2004;201(2):167\u201380.","journal-title":"J Cell Physiol"},{"issue":"7","key":"746_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2340\/00015555-2472","volume":"96","author":"S Steinke","year":"2017","unstructured":"Steinke S, Gutknecht M, Zeidler C, et al. Cost-effectiveness of an 8% capsaicin patch in the treatment of brachioradial pruritus and notalgia paraesthetica, two forms of neuropathic pruritus. Acta Derm Venereol. 2017;96(7):71\u20136.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"746_CR18","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.jaad.2010.07.036","volume":"65","author":"M Marziniak","year":"2011","unstructured":"Marziniak M, Phan NQ, Raap U, et al. Brachioradial pruritus as a result of cervical spine pathology: the results of a magnetic resonance tomography study. J Am Acad Dermatol. 2011;65(4):756\u201362.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"746_CR19","doi-asserted-by":"publisher","first-page":"535","DOI":"10.2340\/00015555-1344","volume":"92","author":"T Huesmann","year":"2012","unstructured":"Huesmann T, Cunha PR, Osada N, et al. Notalgia paraesthetica: a descriptive two-cohort study of 65 patients from Brazil and Germany. Acta Derm Venereol. 2012;92(5):535\u201340.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"746_CR20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1610-0387.2009.07213_supp.x","volume":"8","author":"NQ Phan","year":"2010","unstructured":"Phan NQ, Siepmann D, Gralow I, Stander S. Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. J Dtsch Dermatol Ges. 2010;8(2):88\u201391.","journal-title":"J Dtsch Dermatol Ges."},{"issue":"9","key":"746_CR21","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00105-006-1180-1","volume":"57","author":"S Stander","year":"2006","unstructured":"Stander S, Reinhardt HW, Luger TA. Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus. Hautarzt. 2006;57(9):801\u20137.","journal-title":"Hautarzt."},{"key":"746_CR22","doi-asserted-by":"publisher","unstructured":"Maul JT, Kretschmer L, Anzengruber F, et al. Impact of UVA on pruritus during UVA\/B phototherapy of inflammatory skin diseases: a randomized double-blind study. J Eur Acad Dermatol Venereol. 2016. doi:10.1111\/jdv.13994 \n                           (Epub ahead of print).","DOI":"10.1111\/jdv.13994"},{"issue":"4","key":"746_CR23","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/ki.2013.454","volume":"87","author":"T Mettang","year":"2015","unstructured":"Mettang T, Kremer AE. Uremic pruritus. Kidney Int. 2015;87(4):685\u201391.","journal-title":"Kidney Int"},{"issue":"3","key":"746_CR24","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jhep.2012.04.023","volume":"57","author":"S Decock","year":"2012","unstructured":"Decock S, Roelandts R, Steenbergen WV, et al. Cholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study. J Hepatol. 2012;57(3):637\u201341.","journal-title":"J Hepatol"},{"issue":"6","key":"746_CR25","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/j.1468-3083.2009.03479.x","volume":"24","author":"L Perez-Perez","year":"2010","unstructured":"Perez-Perez L, Allegue F, Fabeiro JM, et al. Notalgia paresthesica successfully treated with narrow-band UVB: report of five cases. J Eur Acad Dermatol Venereol. 2010;24(6):730\u20132.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"746_CR26","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1468-3083.2010.03865.x","volume":"25","author":"S Hammes","year":"2011","unstructured":"Hammes S, Hermann J, Roos S, Ockenfels HM. UVB 308-nm excimer light and bath PUVA: combination therapy is very effective in the treatment of prurigo nodularis. J Eur Acad Dermatol Venereol. 2011;25(7):799\u2013803.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"746_CR27","doi-asserted-by":"crossref","unstructured":"Nakamura M, Koo JY. Phototherapy for the treatment of prurigo nodularis: a review. Dermatol Online J. 2016;22(4) (pii: 13030\/qt4b07778z).","DOI":"10.5070\/D3224030653"},{"issue":"2\u20133","key":"746_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","volume":"47","author":"S Matsuda","year":"2000","unstructured":"Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000;47(2\u20133):119\u201325.","journal-title":"Immunopharmacology."},{"issue":"5","key":"746_CR29","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/j.1365-2133.1995.tb00729.x","volume":"132","author":"J Berth-Jones","year":"1995","unstructured":"Berth-Jones J, Smith SG, Graham-Brown RA. Nodular prurigo responds to cyclosporin. Br J Dermatol. 1995;132(5):795\u20139.","journal-title":"Br J Dermatol"},{"key":"746_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.neuroscience.2016.06.057","volume":"338","author":"M Kremer","year":"2016","unstructured":"Kremer M, Salvat E, Muller A, et al. Antidepressants and gabapentinoids in neuropathic pain: mechanistic insights. Neuroscience. 2016;338:183\u2013206.","journal-title":"Neuroscience"},{"issue":"4","key":"746_CR31","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40257-016-0198-0","volume":"17","author":"MP Pereira","year":"2016","unstructured":"Pereira MP, Kremer AE, Mettang T, Stander S. Chronic pruritus in the absence of skin disease: pathophysiology, diagnosis and treatment. Am J Clin Dermatol. 2016;17(4):337\u201348.","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"746_CR32","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1001\/archderm.141.12.1507","volume":"141","author":"PD Yesudian","year":"2005","unstructured":"Yesudian PD, Wilson NJ. Efficacy of gabapentin in the management of pruritus of unknown origin. Arch Dermatol. 2005;141(12):1507\u20139.","journal-title":"Arch Dermatol"},{"issue":"5","key":"746_CR33","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jpainsymman.2006.07.006","volume":"32","author":"G Porzio","year":"2006","unstructured":"Porzio G, Aielli F, Verna L, et al. Efficacy of pregabalin in the management of cetuximab-related itch. J Pain Symptom Manag. 2006;32(5):397\u20138.","journal-title":"J Pain Symptom Manag"},{"issue":"12","key":"746_CR34","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1093\/ndt\/gfh496","volume":"19","author":"AI Gunal","year":"2004","unstructured":"Gunal AI, Ozalp G, Yoldas TK, et al. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant. 2004;19(12):3137\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"2 Suppl.","key":"746_CR35","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/j.jaad.2007.07.017","volume":"58","author":"J Ehrchen","year":"2008","unstructured":"Ehrchen J, Stander S. Pregabalin in the treatment of chronic pruritus. J Am Acad Dermatol. 2008;58(2 Suppl.):S36\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"746_CR36","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1159\/000012386","volume":"69","author":"M Biondi","year":"2000","unstructured":"Biondi M, Arcangeli T, Petrucci RM. Paroxetine in a case of psychogenic pruritus and neurotic excoriations. Psychother Psychosom. 2000;69(3):165\u20136.","journal-title":"Psychother Psychosom"},{"issue":"2","key":"746_CR37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0885-3924(98)00048-7","volume":"16","author":"Z Zylicz","year":"1998","unstructured":"Zylicz Z, Smits C, Krajnik M. Paroxetine for pruritus in advanced cancer. J Pain Symptom Manag. 1998;16(2):121\u20134.","journal-title":"J Pain Symptom Manag"},{"issue":"7","key":"746_CR38","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1182\/blood.V99.7.2627","volume":"99","author":"A Tefferi","year":"2002","unstructured":"Tefferi A, Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood. 2002;99(7):2627.","journal-title":"Blood"},{"issue":"3","key":"746_CR39","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/S0885-3924(02)00645-0","volume":"25","author":"MP Davis","year":"2003","unstructured":"Davis MP, Frandsen JL, Walsh D, et al. Mirtazapine for pruritus. J Pain Symptom Manag. 2003;25(3):288\u201391.","journal-title":"J Pain Symptom Manag"},{"issue":"7","key":"746_CR40","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/AJP.0b013e31826b1329","volume":"29","author":"H Knotkova","year":"2013","unstructured":"Knotkova H, Portenoy RK, Cruciani RA. Transcranial direct current stimulation (tDCS) relieved itching in a patient with chronic neuropathic pain. Clin J Pain. 2013;29(7):621\u20132.","journal-title":"Clin J Pain"},{"issue":"Suppl. 2","key":"746_CR41","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000440829","volume":"33","author":"AE Kremer","year":"2015","unstructured":"Kremer AE, Namer B, Bolier R, et al. Pathogenesis and management of pruritus in PBC and PSC. Dig Dis. 2015;33(Suppl. 2):164\u201375.","journal-title":"Dig Dis"},{"issue":"9041","key":"746_CR42","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/S0140-6736(96)04176-1","volume":"348","author":"G Peer","year":"1996","unstructured":"Peer G, Kivity S, Agami O, et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet. 1996;348(9041):1552\u20134.","journal-title":"Lancet"},{"issue":"4","key":"746_CR43","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jaad.2009.08.052","volume":"63","author":"NQ Phan","year":"2010","unstructured":"Phan NQ, Bernhard JD, Luger TA, Stander S. Antipruritic treatment with systemic mu-opioid receptor antagonists: a review. J Am Acad Dermatol. 2010;63(4):680\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"746_CR44","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/ACI.0000000000000199","volume":"15","author":"T Werfel","year":"2015","unstructured":"Werfel T, Biedermann T. Current novel approaches in systemic therapy of atopic dermatitis: specific inhibition of cutaneous Th2 polarized inflammation and itch. Curr Opin Allergy Clin Immunol. 2015;15(5):446\u201352.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"2","key":"746_CR45","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","volume":"371","author":"LA Beck","year":"2014","unstructured":"Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130\u20139.","journal-title":"N Engl J Med"},{"issue":"24","key":"746_CR46","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"2","key":"746_CR47","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1056\/NEJMoa1501646","volume":"373","author":"KB Gordon","year":"2015","unstructured":"Gordon KB, Duffin KC, Bissonnette R, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373(2):136\u201344.","journal-title":"N Engl J Med"},{"issue":"2","key":"746_CR48","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jaci.2008.05.047","volume":"122","author":"U Raap","year":"2008","unstructured":"Raap U, Wichmann K, Bruder M, et al. Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol. 2008;122(2):421\u20133.","journal-title":"J Allergy Clin Immunol."},{"issue":"2","key":"746_CR49","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14207","volume":"174","author":"O Nemoto","year":"2016","unstructured":"Nemoto O, Furue M, Nakagawa H, et al. The first trial of CIM331, a humanized anti-human IL-31 receptor A antibody, for healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomised, double-blind, placebo-controlled study. Br J Dermatol. 2016;174(2):296\u2013304.","journal-title":"Br J Dermatol"},{"key":"746_CR50","unstructured":"Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494\u2013503.e494."},{"issue":"5","key":"746_CR51","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/bjd.14871","volume":"175","author":"R Bissonnette","year":"2016","unstructured":"Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175(5):902\u201311.","journal-title":"Br J Dermatol"},{"issue":"3","key":"746_CR52","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1124\/jpet.115.223784","volume":"354","author":"T Fukuyama","year":"2015","unstructured":"Fukuyama T, Ehling S, Cook E, Baumer W. Topically administered Janus-kinase inhibitors tofacitinib and oclacitinib display impressive antipruritic and anti-inflammatory responses in a model of allergic dermatitis. J Pharmacol Exp Ther. 2015;354(3):394\u2013405.","journal-title":"J Pharmacol Exp Ther"},{"key":"746_CR53","doi-asserted-by":"crossref","unstructured":"Feldman SR, Thaci D, Gooderham M, et al. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(6):1162\u201370.e1163.","DOI":"10.1016\/j.jaad.2016.07.040"},{"issue":"4","key":"746_CR54","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/cncr.28441","volume":"120","author":"S Verstovsek","year":"2014","unstructured":"Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014;120(4):513\u201320.","journal-title":"Cancer"},{"issue":"4","key":"746_CR55","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/j.1365-2133.2006.07405.x","volume":"155","author":"L Dubertret","year":"2006","unstructured":"Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006;155(4):729\u201336.","journal-title":"Br J Dermatol"},{"issue":"10","key":"746_CR56","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1111\/jdv.13150","volume":"29","author":"PC van de Kerkhof","year":"2015","unstructured":"van de Kerkhof PC, Reich K, Kavanaugh A, et al. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. J Eur Acad Dermatol Venereol. 2015;29(10):2002\u201310.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"746_CR57","doi-asserted-by":"publisher","first-page":"514","DOI":"10.2340\/00015555-2360","volume":"96","author":"JM Sobell","year":"2016","unstructured":"Sobell JM, Foley P, Toth D, et al. Effects of apremilast on pruritus and skin discomfort\/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis. Acta Derm Venereol. 2016;96(4):514\u201320.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"746_CR58","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/jdv.12761","volume":"29","author":"U Mrowietz","year":"2015","unstructured":"Mrowietz U, Chouela EN, Mallbris L, et al. Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study. J Eur Acad Dermatol Venereol. 2015;29(6):1114\u201320.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"746_CR59","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis: results of two phase 3 trials. N Engl J Med. 2014;371(4):326\u201338.","journal-title":"N Engl J Med"},{"issue":"3","key":"746_CR60","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","volume":"73","author":"D Thaci","year":"2015","unstructured":"Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"746_CR61","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345\u201356.","journal-title":"N Engl J Med"},{"issue":"3","key":"746_CR62","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418\u201331.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"746_CR63","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1046\/j.1365-2133.2002.04803.x","volume":"147","author":"M Toyoda","year":"2002","unstructured":"Toyoda M, Nakamura M, Makino T, et al. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol. 2002;147(1):71\u20139.","journal-title":"Br J Dermatol"},{"issue":"2\u20133","key":"746_CR64","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ejphar.2004.03.047","volume":"491","author":"T Ohmura","year":"2004","unstructured":"Ohmura T, Hayashi T, Satoh Y, et al. Involvement of substance P in scratching behaviour in an atopic dermatitis model. Eur J Pharmacol. 2004;491(2\u20133):191\u20134.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"746_CR65","doi-asserted-by":"publisher","first-page":"e10968","DOI":"10.1371\/journal.pone.0010968","volume":"5","author":"S Stander","year":"2010","unstructured":"Stander S, Siepmann D, Herrgott I, et al. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010;5(6):e10968.","journal-title":"PLoS One"},{"key":"746_CR66","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/978-3-662-44605-8_14","volume":"226","author":"S Stander","year":"2015","unstructured":"Stander S, Luger TA. NK-1 antagonists and itch. Handb Exp Pharmacol. 2015;226:237\u201355.","journal-title":"Handb Exp Pharmacol"},{"issue":"12","key":"746_CR67","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00424-013-1284-2","volume":"465","author":"T Liu","year":"2013","unstructured":"Liu T, Ji RR. New insights into the mechanisms of itch: are pain and itch controlled by distinct mechanisms? Pflugers Arch. 2013;465(12):1671\u201385.","journal-title":"Pflugers Arch"},{"issue":"3","key":"746_CR68","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1254\/jphs.FP0050564","volume":"99","author":"N Takano","year":"2005","unstructured":"Takano N, Sakurai T, Kurachi M. Effects of anti-nerve growth factor antibody on symptoms in the NC\/Nga mouse, an atopic dermatitis model. J Pharmacol Sci. 2005;99(3):277\u201386.","journal-title":"J Pharmacol Sci."},{"issue":"5","key":"746_CR69","doi-asserted-by":"publisher","first-page":"542","DOI":"10.2340\/00015555-2047","volume":"95","author":"D Roblin","year":"2015","unstructured":"Roblin D, Yosipovitch G, Boyce B, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis. Acta Derm Venereol. 2015;95(5):542\u20138.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"746_CR70","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/1346-8138.12726","volume":"42","author":"Y Murata","year":"2015","unstructured":"Murata Y, Song M, Kikuchi H, et al. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis. J Dermatol. 2015;42(2):129\u201339.","journal-title":"J Dermatol"},{"key":"746_CR71","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/978-3-662-44605-8_16","volume":"226","author":"A Cowan","year":"2015","unstructured":"Cowan A, Kehner GB, Inan S. Targeting itch with ligands selective for kappa opioid receptors. Handb Exp Pharmacol. 2015;226:291\u2013314.","journal-title":"Handb Exp Pharmacol"},{"key":"746_CR72","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2147\/CCID.S55942","volume":"8","author":"S Inui","year":"2015","unstructured":"Inui S. Nalfurafine hydrochloride to treat pruritus: a review. Clin Cosmet Investig Dermatol. 2015;8:249\u201355.","journal-title":"Clin Cosmet Investig Dermatol."},{"issue":"12","key":"746_CR73","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1681\/ASN.2005020152","volume":"16","author":"B Wikstrom","year":"2005","unstructured":"Wikstrom B, Gellert R, Ladefoged SD, et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol. 2005;16(12):3742\u20137.","journal-title":"J Am Soc Nephrol"},{"key":"746_CR74","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12882-015-0043-3","volume":"16","author":"A Hawi","year":"2015","unstructured":"Hawi A, Alcorn H Jr, Berg J, et al. Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus. BMC Nephrol. 2015;16:47.","journal-title":"BMC Nephrol."},{"issue":"1","key":"746_CR75","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/hep.26909","volume":"60","author":"U Beuers","year":"2014","unstructured":"Beuers U, Kremer AE, Bolier R, Elferink RP. Pruritus in cholestasis: facts and fiction. Hepatology. 2014;60(1):399\u2013407.","journal-title":"Hepatology"},{"issue":"4","key":"746_CR76","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/hep.23821","volume":"52","author":"EM Kuiper","year":"2010","unstructured":"Kuiper EM, van Erpecum KJ, Beuers U, et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology. 2010;52(4):1334\u201340.","journal-title":"Hepatology"},{"issue":"1","key":"746_CR77","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12876-016-0481-9","volume":"16","author":"VS Hegade","year":"2016","unstructured":"Hegade VS, Kendrick SF, Dobbins RL, et al. BAT117213: ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial. BMC Gastroenterol. 2016;16(1):71.","journal-title":"BMC Gastroenterol."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-017-0746-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0746-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0746-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T16:48:55Z","timestamp":1659113335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-017-0746-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,2]]},"references-count":77,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["746"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0746-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,2]]},"assertion":[{"value":"2 May 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This article was supported by the German Federal Ministry of Education and Research (BMBF; No. 01KG1305 to SS), the Interdisciplinary Center for Clinical Research (IZKF; No. CTRP 07 to SS), and by the European Academy for Dermatology and Venereology (EADV, No. 2016-012 to MPP).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MPP declares that he has no conflicts of interest that are directly relevant to the content of this article. SS has consulted for Beiersdorf, Galderma, Helsinn, Menlo, Nerre, and Trevi.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}